Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
356559-20-1
InChi: InChI=1S/C27H29N5O/c28-26-25-24(21-8-4-9-23(14-21)33-17-19-6-2-1-3-7-19)16-32(27(25)30-18-29-26)22-12-20(13-22)15-31-10-5-11-31/h1-4
GSK1904529A (72 h) inhibits tumor cells proliferation with IC50s ranges from 35 nM to >30 μM
Drugs in development for Parkinson's disease
PubMed PMID: 21249167
VX-770 Size:2mg solid 356559-20-1VX 770, is a drug used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, who account for 45% cases of cystic fibrosis, and is included in a combination drug, lumacaftor ivacaftor, which is used to treat people with cystic fibrosis who have the F508del mutation in CFTR. Ivacaftor is a "potentiator" of CFTR, meaning it increases the probability that the defective channel
US$ 65.00
US$ 75.00
US$ 85.00
US$ 125.00
US$ 38.00
US$ 98.00
US$ 38.00